Company intelligence / Profile preview

Egetis Therapeutics

Ownership: Public · EGTX
Employees: ~40
Development stage: Other

Overview

Emcitate® demonstrated significant reduction in T3 levels and positive secondary endpoints in MCT8 deficiency patients; approved by the European Commission as the first treatment for this indication. US registration studies are ongoing. Aladote® showed successful proof-of-principle results for reducing risk of acute liver injury after paracetamol overdose; further development on hold pending completion of Emcitate regulatory milestones.[5][6][7]

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Small molecules (tiratricol, calmangafodipir)[6][8]
Industry: Biotech

Drug pipeline

2 assets

tiratricol

Approved

1 more asset in the full pipeline.

Partnerships

License agreement with Fujimoto Pharmaceutical Co., Ltd. for Emcitate commercialization in Japan[5].

Financials

Market cap: $523.6M
Total revenue: $6.3M
Enterprise value: $492.3M

Beyond the preview

Go deeper on Egetis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Egetis Therapeutics.